Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

ImmunoGen Inc. ($IMGN) stock scaled 29% to close at $2.04 in its previous trading session. The stock movement corresponded to the news of its drug candidate mirvetuximab soravtansine showing encouraging results in responding to and improving progression-free survival (PFS) in folate receptor alpha positive platinum-resistant ovarian cancer patients.
The stock had a rocky performance in 2016 as it lost close to 85% of its value. However, the latest news is likely to bring the stock back on upward trajectory. Late last year, it also reported its quarterly results for the period ended September 30, 2016. The company had sustained loss of $44.7 million for the said time period.

AstraZeneca ($AZN) is likely to have a strong year ahead. The company has been named by Credit Suisse as one of its potential surprise stocks for the year. Credit Suisse stated that AstraZeneca has a strong pipeline which will help its future prospects. The initial results from its MYSTIC lung cancer study are encouraging. The company also had high approval rate in 2016.
In the current year, AstraZeneca will look to expand the use of Tagrisso to treat early stage lung cancer. It may also extend Lynparza for treating breast cancer. Other potential candidates in its pipeline are tralokinumab for treating severe asthma and roxadustat foranemia.


• Mylan ($MYL) announced the launch of a generic version of Janssen’s Concerta tablets in the US. The product is designed for treating Attention Deficit Hyperactivity Disorder.
• Quorum Health ($QHC) announced closing the sale of its hospital in Winder. According to the deal, the Barrow Regional Medical Center will transfer to Northeast Georgia Health System.

• Opko Health ($OPK) reported that its hGH-CTP investigational human growth hormone product flunked in a Phase 3 study as it was not able to outperform a placebo.
• Innocoll Holdings($INNL) stock collapsed as the FDA slammed its Xaracoll product.

• Abbott Laboratories ($ABT) received conditional approval in China for its merger with St. Jude Medical ($STJ). The Chinese commerce ministry has asked St. Jude to sell it vascular closure device business to Terumo as part of the agreement.
• China Cord Blood ($CO) stock rocketed as Geo Investing points to a tentative sale/purchase agreement indicating a much higher price than market.

• Biogen ($BIIB) receives price target upgrade from BMO Capital. The stock’s new price target is $68, up from $61 apiece.
• Innocoll Holdings($INNL) receives rating downgrade from Outperform to Market Perform

Gainers (% price change) Last Trade Change Mkt Cap
ImmunoGen, Inc.
2.04 +0.46 (29.11%) 173.70M
China Cord Blood Corp
6.12 +0.65 (11.88%) 455.95M
Harvard Bioscience, Inc.
3.05 +0.15 (5.17%) 106.68M
Pacira Pharmaceuticals
32.30 +1.05 (3.36%) 1.22B
Flamel Tech. S.A. (ADR)
10.39 +0.33 (3.28%) 438.97M
Losers (% price change)
Accelerate Diagnostics
20.75 -0.90 (-4.16%) 1.06B
AcelRx Pharmaceuticals
2.60 -0.10 (-3.70%) 113.66M
Dynavax Tech. Corp.
3.95 -0.15 (-3.66%) 157.96M
Zogenix, Inc.
12.15 -0.45 (-3.57%) 304.84M
Endocyte, Inc.
2.55 -0.09 (-3.41%) 108.19M
Most Actives (dollar volume)
Gilead Sciences, Inc.
71.61 -0.52 (-0.72%) 93.51B
Johnson & Johnson
115.21 -0.28 (-0.24%) 314.49B
Merck & Co., Inc.
58.87 -0.17 (-0.29%) 161.68B
Pfizer Inc.
32.48 -0.01 (-0.03%) 197.95B
Amgen, Inc.
146.21 -1.57 (-1.06%) 108.85B